Clinical trials offer a chance to benefit from the latest therapeutic innovations. However, only less than <5% of cancer patients take part in clinical trials, whereas over 70% of patients would be willing to participate if they knew about them and up to 20% of trials fail due to lack of participants.
This is the problem that French startup Klineo aims to address. It offers a solution that simplifies the complex and time-consuming trial search process for both patients and doctors.
Investment to span across all types of cancer
The French digital health startup just announced the raise of €2 million in funding. The investment came from BPI and business angels. It will enable Klineo to cover all cancers in France by the end of 2024, with a near-future extension to lung cancer.
The company also plans to expand to other countries (Europe, USA, etc.) and other pathologies (rare and neurological diseases, etc.). In addition, the funds will enable Klineo to expand its team and continue to improve the platform both medically and technologically.
AI-based platform for cancer trials
Klineo was founded in 2021 by a medical oncologist from the Gustave Roussy Institute in Paris and two engineers – Thomas Peyresblanques and Nicolas Drizard from the École Polytechnique, one of France’s most prestigious schools of engineering.
Klineo initiated a pilot project at the Gustave Roussy Institute in 2022 and launched the first national platform for triple-negative breast cancer in collaboration with a patient association, the Collectif Triplettes Roses.
Its AI-based platform connects doctors and patients directly with relevant trials in less than a minute. This fast and intuitive solution democratises access to new treatments for patients.
Received immense support
In 2023, Klineo extended its platform to include new cancers – breast, skin, lymphoma, etc. It also benefits from the support of several players, including the BPI, the Pfizer Healthcare Hub, Wilco, Onconumérique, PariSanté Campus, and Unicancer.
Also, it works in partnership with both industrial sponsors (Pfizer, AstraZeneca, Pierre Fabre, MSD, etc.) and academic institutions (Unicancer, LYSARC, etc.).
According to Dr Arnaud Bayle, co-founder of Klineo and oncologist said: “Today, too few patients benefit from a clinical trial because the search for one is a very tedious process. At Klineo, we offer a reliable, intuitive, and fast solution that finally gives doctors and patients, wherever they are treated, the possibility of easily finding new therapeutic options adapted to each situation, and which ultimately enables medical research to progress.”
“The trust and support of our investors reflect the importance of our mission: to guarantee fair access to clinical trials. This round of funding will enable us to expand our platform to all types of cancer, thereby accelerating the inclusion of patients in clinical trials,” added Thomas Peyresblanques, CEO of Klineo.
